The 6th World Health Expo, hosted by the National Health Commission, Hubei Provincial Government, and Wuhan Municipal Government, and organized by the Hubei Chushang Federation, recently opened in Wuhan. At the event, Nurofex® (Opvika, Eperadogene Emaparvovec Ophthalmic Injection), a gene therapy product independently developed by Neurophth, was selected as a "New Brand, New Standard, New Achievement" case and showcased at the expo’s "Three New Innovations" promotion session.

In recent years, China’s innovative pharmaceutical industry has embraced unprecedented opportunities, with breakthroughs in new brands, standards, and achievements. The "Three New Innovations" initiative aims to identify and nurture cutting-edge companies and products, drive deeper integration of technology and industry, and accelerate the formation of an innovation-driven model for health sector development. Nurofex®, leveraging its globally leading gene therapy technology and clinical progress, stood out through rigorous evaluations.

Nurofex® is designed to treat Leber’s Hereditary Optic Neuropathy (LHON) caused by ND4 mutations. As China’s first AAV-based gene therapy product to enter clinical trials, it has received orphan drug designation from the U.S. FDA and European Medicines Agency (EMA), along with regulatory clinical trial approvals in both China and the U.S. To date, Nurofex® has completed patient enrollment for its Phase III trial in China and Phase I/II trial in the U.S., making it the fastest-advancing ophthalmic gene therapy in China, with expected approval in 2025. At the expo, Neurophth also displayed samples of Nurofex® to demonstrate its scientific innovation.

Neurophth remains committed to advancing ophthalmic gene therapy R&D, addressing unmet clinical needs for patients, and leading the industry toward healthy and prosperous growth.